Redeye returns with an update following SciBase Holding’s Q4 report. Sales increased by a strong 45%, slightly above our expectations, while costs came in higher than anticipated. We reiterate our fair value range of SEK0.2–1.3, with a base case of SEK0.5. Looking ahead, we note that 2026 is likely to be an eventful year for the company, with potential initial reimbursement decisions and results from the Kenvue study expected soon.
LÄS MER
